Dr. Inna Rosenblat | PhD, MBA

VP, Clinical Affairs & CRO

Inna holds a PhD in Cancer Research and an MSc in Genetics and Cancer Research from the Faculty of Medicine at Tel Aviv University, as well as an MBA in Strategy and Entrepreneurship from the Faculty of Management at Tel Aviv University. She brings more than 15 years of experience across the pharmaceutical industry, CRO environments, and medical innovation, with broad expertise in the planning and management of clinical research, medical strategy, and strategic partnerships across a range of therapeutic areas, with particular specialization in oncology, hematology, cell and gene therapies, rare diseases, and diagnostics

Throughout her career, Inna has led Phase I–IV clinical programs as well as Real-World Evidence studies, working closely with leading investigators, healthcare organizations, pharmaceutical companies, regulatory authorities, and multidisciplinary teams

In her role at IQVIA, Inna led large-scale strategic partnerships with major healthcare organizations, established meaningful professional relationships with key opinion leaders, hospital directors, and senior healthcare executives, and advanced initiatives in genomics, personalized medicine, and clinical innovation. In her previous roles at AbbVie, she led national clinical operations, managed clinical studies across multiple phases, and promoted integrated collaboration with medical, regulatory, safety, vendor, and CRO stakeholders, with a strong emphasis on strategic planning, quality, and execution excellence

Alongside her industry experience, she has co-authored approximately 20 scientific publications in the fields of oncology and cancer biology, which have been presented at leading international conferences. The combination of scientific depth, operational experience, strategic insight, and a strong ability to build effective collaboration among diverse stakeholders positions Inna as a leading expert in supporting clinical, medical, and strategic initiatives across the healthcare system and the life sciences industry.